GlassScriptPhysician profile
Amer Zarka
NPI 1629096664
$6,034.79
in general payments reported to CMS, 2019-2025
28 companies · $485 in 2025
The $485 reported for 2025 was more than what 78% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,308 · 2020: $747 · 2021: $725 · 2022: $1,427 · 2023: $615 · 2024: $728 · 2025: $485.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,828.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,827.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,145.93 | 2019-2025 | |
| Boston Scientific Corporation | $809.73 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $667.52 | 2020-2024 | Farxiga, Brilinta |
| Amgen INC. | $507.89 | 2019-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $346.71 | 2019-2022 | |
| Abbott Laboratories | $301.88 | 2019-2024 | Assurity |
| Novo Nordisk INC | $257.24 | 2022-2025 | Wegovy, Ozempic |
| Angiodynamics, INC. | $256.00 | 2019 | |
| Scpharmaceuticals INC. | $231.17 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $229.23 | 2021-2025 | Verquvo, Capvaxive |
| Sanofi-Aventis U.S. LLC | $198.62 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $122.47 | 2022-2025 | Jardiance |
| Kiniksa Pharmaceuticals International, Plc | $121.10 | 2024 | Arcalyst |
| Pfizer INC. | $106.62 | 2019-2025 | |
| Cardiovascular Systems INC. | $100.00 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $89.02 | 2024-2025 | |
| Lilly USA, LLC | $88.55 | 2022-2025 | Mounjaro, Zepbound |
| Regeneron Healthcare Solutions, INC. | $77.58 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $71.32 | 2019-2022 | |
| Atricure, INC. | $62.73 | 2024 | |
| Abiomed | $49.21 | 2023-2025 | Impella |
| Lexicon Pharmaceuticals, INC. | $43.09 | 2023-2024 | Inpefa |
| Edwards Lifesciences Corporation | $38.74 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Heartflow, INC. | $29.50 | 2019 | |
| Kiniksa Pharmaceuticals, LTD. | $25.17 | 2023 | Arcalyst |
| Bardy Diagnostics, INC. | $22.82 | 2020 | |
| Exact Sciences Corporation | $21.32 | 2025 | The Cologuard Plus Collection Kit |
| Kestra Medical Technology Services, INC. | $13.63 | 2025 | Assure Wcd |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amer Zarka listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.